Chris Van Tuyl was Appointed as General Counsel at Dermavant

Date of management change: April 03, 2018 

What Happened?

Durham, -based Dermavant Appointed Chris Van Tuyl as General Counsel


About the Company

Dermavant Sciences is dedicated to developing and, upon regulatory approval, commercializing innovative therapies in medical dermatology. Dermavant currently has five investigational drugs in development: RVT-501, RVT-502, RVT-503, RVT-504, and RVT-201. RVT-501 is a highly potent and selective topical phosphodiesterase-4 inhibitor being developed as a topical therapy for patients with mild-to-moderate atopic dermatitis. RVT-502 is a dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor being developed as a topical therapy for a variety of serious dermatologic conditions. RVT-503 is a preclinical asset being studied for the treatment of acne. RVT-504 is a combination of a muscarinic antagonist with a muscarinic agonist being developed as an oral therapy for the treatment of hyperhidrosis. RVT-201 is a caspase-1 inhibitor that acts to inhibit the production of inflammatory cytokines and is being developed as a topical therapy for inflammatory skin diseases.


About the Person

Chris Van Tuyl is General Counsel at Dermavant. Previously, Chris held various senior legal leadership roles in the industry.


Info Source



Other IT executives who recently changed jobs as well: Schlesinger Briansky Sharon, Apolinsky Craig, Benedict Vicky, Camperlengo John, Burt Frank, Rubenstein Rob, Wertheimer Roger, Marsteller Marcia, Fitzgibbon Gerrard, Hazin Karen, Early Michael

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.